Search tips
Search criteria 


Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. 1992 July; 33(7): 922–928.
PMCID: PMC1379405

Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial.


The effect of fish oil on the course of ulcerative colitis was investigated in a randomised blinded controlled study. Eighty seven patients received supplements of 20 ml HiEPA fish oil as triglyceride (4.5 g of eicosapentaenoic acid) or olive oil placebo daily for one year. The oils were given in addition to standard drug therapy and trial entry was stratified for disease activity. Fish oil significantly increased the eicosapentaenoic acid content of rectal mucosa to 3.2% of total fatty acids at six months, compared with 0.63% for patients on olive oil. This was associated with increased synthesis of leukotriene B5, and 53% suppression of leukotriene B4 synthesis by ionophore--stimulated neutrophils. Leukotriene B4 suppression persisted for at least two months after treatment was stopped. Treatment with fish oil resulted in measurable, but only limited clinical benefit. For patients entering the trial in relapse (n = 53), there was a significant reduction in corticosteroid requirement after one and two months treatment. There was a trend towards achieving remission (off corticosteroids) faster in the patients on fish oil, although differences were not significant. For patients in remission at trial entry or during the trial (n = 69), there was no significant difference in the rate of relapse by log rank analysis. We conclude that fish oil supplementation produces a modest corticosteroid sparing effect in active disease, but there is no benefit in maintenance therapy.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980 Jul 17;286(5770):264–265. [PubMed]
  • Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984 Mar;86(3):453–460. [PubMed]
  • Lobos EA, Sharon P, Stenson WF. Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4. Dig Dis Sci. 1987 Dec;32(12):1380–1388. [PubMed]
  • Lee TH, Hoover RL, Williams JD, Sperling RI, Ravalese J, 3rd, Spur BW, Robinson DR, Corey EJ, Lewis RA, Austen KF. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 1985 May 9;312(19):1217–1224. [PubMed]
  • Hawthorne AB, Filipowicz BL, Edwards TJ, Hawkey CJ. High dose eicosapentaenoic acid ethyl ester: effects on lipids and neutrophil leukotriene production in normal volunteers. Br J Clin Pharmacol. 1990 Aug;30(2):187–194. [PubMed]
  • Prescott SM, Zimmerman GA, Morrison AR. The effects of a diet rich in fish oil on human neutrophils: identification of leukotriene B5 as a metabolite. Prostaglandins. 1985 Aug;30(2):209–227. [PubMed]
  • Goldman DW, Pickett WC, Goetzl EJ. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun. 1983 Nov 30;117(1):282–288. [PubMed]
  • Lee TH, Menica-Huerta JM, Shih C, Corey EJ, Lewis RA, Austen KF. Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem. 1984 Feb 25;259(4):2383–2389. [PubMed]
  • Terano T, Salmon JA, Higgs GA, Moncada S. Eicosapentaenoic acid as a modulator of inflammation. Effect on prostaglandin and leukotriene synthesis. Biochem Pharmacol. 1986 Mar 1;35(5):779–785. [PubMed]
  • Robinson DR, Prickett JD, Makoul GT, Steinberg AD, Colvin RB. Dietary fish oil reduces progression of established renal disease in (NZB x NZW)F1 mice and delays renal disease in BXSB and MRL/1 strains. Arthritis Rheum. 1986 Apr;29(4):539–546. [PubMed]
  • Vilaseca J, Salas A, Guarner F, Rodríguez R, Martínez M, Malagelada JR. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut. 1990 May;31(5):539–544. [PMC free article] [PubMed]
  • Bittiner SB, Tucker WF, Cartwright I, Bleehen SS. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet. 1988 Feb 20;1(8582):378–380. [PubMed]
  • Bjørneboe A, Søyland E, Bjørneboe GE, Rajka G, Drevon CA. Effect of dietary supplementation with eicosapentaenoic acid in the treatment of atopic dermatitis. Br J Dermatol. 1987 Oct;117(4):463–469. [PubMed]
  • Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaouette J, Timchalk M, Beeler D, Lininger L. Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann Intern Med. 1987 Apr;106(4):497–503. [PubMed]
  • Nishida T, Miwa H, Shigematsu A, Yamamoto M, Iida M, Fujishima M. Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut. 1987 Aug;28(8):1002–1007. [PMC free article] [PubMed]
  • Pacheco S, Hillier K, Smith C. Increased arachidonic acid levels in phospholipids of human colonic mucosa in inflammatory bowel disease. Clin Sci (Lond) 1987 Oct;73(4):361–364. [PubMed]
  • McCall TB, O'Leary D, Bloomfield J, O'Moráin CA. Therapeutic potential of fish oil in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1989 Oct;3(5):415–424. [PubMed]
  • Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n--3-omega-fatty acid: an open trial. J Clin Gastroenterol. 1990 Apr;12(2):157–161. [PubMed]
  • Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967 Aug;20(8):637–648. [PubMed]
  • Wiles SJ, Nettleton PA, Black AE, Paul AA. The nutrient composition of some cooked dishes eaten in Britain: a supplementary food composition table. J Hum Nutr. 1980 Jun;34(3):189–223. [PubMed]
  • Broadhurst AJ, Wharf SG, Stockley L. Fatty acid composition of selected foods consumed in a mixed diet study. Hum Nutr Appl Nutr. 1987 Apr;41(2):96–100. [PubMed]
  • Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989 Feb 2;320(5):265–271. [PubMed]
  • Sperling RI, Weinblatt M, Robin JL, Ravalese J, 3rd, Hoover RL, House F, Coblyn JS, Fraser PA, Spur BW, Robinson DR, et al. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum. 1987 Sep;30(9):988–997. [PubMed]
  • Magaro M, Altomonte L, Zoli A, Mirone L, De Sole P, Di Mario G, Lippa S, Oradei A. Influence of diet with different lipid composition on neutrophil chemiluminescence and disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 1988 Oct;47(10):793–796. [PMC free article] [PubMed]
  • Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med. 1988 Mar 3;318(9):549–557. [PubMed]
  • Budiarso IT. Fish oil versus olive oil. Lancet. 1990 Nov 24;336(8726):1313–1314. [PubMed]

Articles from Gut are provided here courtesy of BMJ Group